Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 268

1.

Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC.

Sci Transl Med. 2018 May 16;10(441). pii: eaao4680. doi: 10.1126/scitranslmed.aao4680.

PMID:
29769286
2.

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR.

Pediatr Blood Cancer. 2018 Jul;65(7):e27023. doi: 10.1002/pbc.27023. Epub 2018 Mar 30.

PMID:
29603591
3.

Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM.

Sci Data. 2017 Dec 5;4:170183. doi: 10.1038/sdata.2017.183.

4.

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Kurmashev D, Reynolds CP, Kang M, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26825. Epub 2017 Sep 17.

PMID:
28921800
5.

Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target.

Li W, Zhang Y, Reynolds CP, Pappas D.

Anal Chem. 2017 Jul 18;89(14):7340-7347. doi: 10.1021/acs.analchem.7b00377. Epub 2017 Jul 7.

PMID:
28656755
6.

Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres.

Dagg RA, Pickett HA, Neumann AA, Napier CE, Henson JD, Teber ET, Arthur JW, Reynolds CP, Murray J, Haber M, Sobinoff AP, Lau LMS, Reddel RR.

Cell Rep. 2017 Jun 20;19(12):2544-2556. doi: 10.1016/j.celrep.2017.05.087.

7.

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

Cooper JP, Reynolds CP, Cho H, Kang MH.

Exp Biol Med (Maywood). 2017 Jun;242(11):1178-1184. doi: 10.1177/1535370217706952. Epub 2017 Apr 21. Review.

8.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Mohrbacher AM, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman EM, Maurer BJ.

Clin Cancer Res. 2017 Aug 15;23(16):4550-4555. doi: 10.1158/1078-0432.CCR-17-0234. Epub 2017 Apr 18.

PMID:
28420721
9.

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM.

Sci Data. 2017 Mar 28;4:170033. doi: 10.1038/sdata.2017.33. Erratum in: Sci Data. 2017 Dec 05;4:170183.

10.

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP.

Int J Cancer. 2017 Jul 15;141(2):405-413. doi: 10.1002/ijc.30706. Epub 2017 May 9.

PMID:
28340497
11.

Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.

Makena MR, Koneru B, Nguyen TH, Kang MH, Reynolds CP.

Mol Cancer Ther. 2017 Apr;16(4):649-661. doi: 10.1158/1535-7163.MCT-16-0749. Epub 2017 Jan 23.

12.

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.

Chen NE, Maldonado NV, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP.

Mol Cancer Ther. 2016 Nov;15(11):2653-2664. Epub 2016 Aug 16.

13.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27.

14.

Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer.

Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, Yang S, Ogura J, Ganapathy V, Bhutia YD.

Br J Pharmacol. 2016 Dec;173(23):3292-3306. doi: 10.1111/bph.13616. Epub 2016 Oct 18.

15.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26263. Epub 2016 Sep 21.

16.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

17.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.

Oncotarget. 2016 Jun 10;8(31):50489-50499. doi: 10.18632/oncotarget.9929. eCollection 2017 Aug 1.

18.

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Oct;63(10):1744-52. doi: 10.1002/pbc.26064. Epub 2016 May 30.

19.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP.

Pediatr Blood Cancer. 2016 Aug;63(8):1349-56. doi: 10.1002/pbc.25994. Epub 2016 Apr 19.

PMID:
27092812
20.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

Supplemental Content

Loading ...
Support Center